儿科药物遗传学:在阿卜杜勒阿齐兹国王大学牙科诊所对CYP2C8多态的分析
Amina M Bagher1, Rania A Aboud2, Noura M Alkinaidri2
1Department of Pharmacology and Toxicology, Faculty of Pharmacy, 37848 King Abdulaziz University , Jeddah, Saudi Arabia.
Drug metabolism and personalized therapy
|November 6, 2024
概括
影响ibuprofen代谢的CYP2C8的遗传变异在沙特儿童中更为频繁. 这表明,在这个人群中,药物反应可能会变化,影响儿科疼痛和炎症管理.
科学领域:
- 药物基因组学 药物基因组学
- 遗传学 遗传学 是一个
- 儿科药理学 儿科药理学
背景情况:
- 布洛芬是一种常见的NSAID治疗儿科疼痛和炎症,由CYP2C8.8代谢.
- CYP2C8 基因变异 (*2, *3, *4) 可以损害布洛芬代谢,增加不良反应风险.
研究的目的:
- 确定沙特儿童中CYP2C8*2,*3,*4等位基因和基因型的频率.
- 将这些频率与其他全球人口进行比较.
主要方法:
- 一项涉及140名健康沙特儿童 (6-12岁) 的横截面研究.
- 使用聚合酶链反应-限制片段长度多态 (PCR-RFLP) 的唾液DNA分析.
主要成果:
- 在沙特儿科队列中观察到CYP2C8*2,*3和*4等位基因的高频率.
- 详细介绍了CYP2C8*2,*3和*4的特定基因型频率.
- 对CYP2C8*2,*3和*4的等位基因频率分别为7.5%,8.57%和1.07%.
结论:
- 与其他亚洲人群相比,沙特儿童中CYP2C8多态的等位素频率显著更高.
- 这表明沙特人对CYP2C8代谢的药物,包括布洛芬,药物反应的可能性更高.
相关概念视频
Pharmacokinetics in Pediatric Patients: Drug Metabolism
410
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
410
Pharmacokinetics in Pediatric Patients: Drug Excretion
408
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
408
Principles of Pharmacogenetics: Types of Genetic Variants
138
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
138
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
159
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
159
Pharmacogenetics of Drug Metabolism: Overview
194
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
194
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
338
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450...
338


